A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors
Primary Purpose
Solid Tumor, Neoplasms, Malignant Tumor
Status
Recruiting
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
ES102
JS001
Sponsored by

About this trial
This is an interventional treatment trial for Solid Tumor focused on measuring ES102, JS001, OX40, PD-1, Solid Tumors, Phase 1, INBRX-106
Eligibility Criteria
Inclusion Criteria:
- 1.Males or females aged ≥18 years.
- 2.Ability to understand and the willingness to sign a written informed consent form.
- 3.Subjects with pathological or cytological diagnosed advanced solid tumor, whose disease has progressed despite standard therapies, or for whom no further standard therapy exists, or who is unsuitable for available standard therapies and at least has progressed after receiving first line therapy.
- 4.All subjects with NSCLC have documentation of absence of tumor activating EGFR mutation and absence of ALK and ROS1 gene rearrangements.
- 5.PD-L1 by IHC: Parts 1 and Part 2 D3-D5: IHC result mandatory but any score allowed. Part 2 D1-D2: Tumor Proportion Score (TPS) ≥ 1%.
- 6.At least one measurable lesion is required (RECIST v1.1)
- 7.Adequate hematologic, coagulation, hepatic and renal function as defined per protocol.
- 8.Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1.
- 9.Estimated life expectancy, in the judgment of the investigator, of at least 12 weeks.
- 10.Male and female subjects of childbearing potential and their spouses must be willing to use feasible contraceptive methods considered effective by the investigator, from the time of signing informed consent and for the duration of study participation through 3 months, following the last dose of study drug. Postmenopausal women are considered to have no fertility potential only if menostasis lasts for at least 12 months.
Exclusion Criteria:
- 1.Prior exposure to OX40 agonists.
- 2.Receipt of any anticancer investigational product or any approved anticancer drug(s) or biological product(s) within 4 weeks prior to the first dose of study drug with certain exceptions.
- 3.Receipt of non-CNS adjuvant radiation therapy within 1 week prior to the first dose, receipt of radiation therapy within 2 weeks or with radiation pneumonia, have not recovered from radiation-related toxicity or still require hormonal treatment for radiation-related toxicity.
- 4.Known allergies to CHO-produced antibodies, which in the opinion of the Investigator suggests an increased potential for an adverse hypersensitivity to ES102.
- 5.Subjects with allergic reactions to the active ingredients of JS001 or any of the excipients.
- 6.Treatment with systemic immunosuppressive medications within 4 weeks prior to the first dose of study drug. Certain exceptions as defined in protocol apply.
- 7.Receipt of live viral vaccine treatment within 4 weeks prior to the first dose of the study drug.
- 8.Prior organ allograft transplantations or allogeneic peripheral blood stem cell (PBSC) or bone marrow (BM) transplantation.
- 9.Subjects with primary or metastatic brain or meningeal tumors.
- 10.Grade ≥ 3 immune-related adverse events (irAEs) or irAE that lead to discontinuation of prior immunotherapy. Some exceptions as defined per protocol apply.
- 11.Subject has not recovered from all AEs of previous anticancer therapies to baseline or ≤ Grade 1 per CTCAE v5.0 before the first dose of study drug. Certain exceptions as defined in protocol apply.
- 12.Hematologic malignancies.
- 13.Receipt of treatment with G-CSF, GM-CSF, Thrombopoietic drugs or EPO within 14 days prior to the first dose of the study drug.
- 14.Patients with other malignancies within 2 years before screening shall be excluded in Part B. Some exceptions as defined per protocol apply.
- 15.Active autoimmune disease or documented history of autoimmune disease that required systemic steroids or other immunosuppressive medications. Certain exceptions as defined in protocol apply.
- 16.Active interstitial lung disease (ILD) or pneumonitis or a history of ILD or pneumonitis requiring treatment with steroids or other immunosuppressive medications.
- 17.Clinically significant cardiac condition, including myocardial infarction, uncontrolled angina, cerebrovascular accident, or other acute uncontrolled heart disease < 6 months; left ventricular ejection fraction (LVEF) < 50%; New York Heart Association (NYHA) Class III or IV congestive heart failure; or uncontrolled hypertension.
- 18.History of pulmonary embolism within 12 weeks prior to the first dose of study drug administration.
- 19.Major surgery within 4 weeks prior to enrollment on this trial.
- 20.History of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection for Part 1. Exceptions as defined in protocol for Part 2 will apply.
- 21.Receiving the systemic anti-infectious drug treatments within 4 weeks prior to the first dose of study drug.
- 22.Pregnant or nursing females.
- 23.Any known, documented, or suspected history of substance abuse that would preclude subject from participation, certain exceptions as defined in protocol apply.
- 24.The subject is inappropriate to participate in this study for other reasons in the judgment of the Investigator.
Sites / Locations
- Jilin Cancer HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Part 1 ES102 Escalation in combination with JS001
Part 2 ES102 Expansion in combination with JS001
Arm Description
ES102 will be escalated, in combination with JS001, in patients with advanced solid tumors.
Subjects will be treated with ES102 at the RP2D in combination with JS001.
Outcomes
Primary Outcome Measures
MTD
Maximum Tolerated Dose (MTD) of ES102 in combination with JS001
Frequency and severity of adverse events of ES102 in combination with JS001
The safety profile of ES102 in combination with JS001 will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.
RP2D
Recommended Phase 2 Dose (RP2D) of ES102 in combination with JS001
Secondary Outcome Measures
Area under the serum concentration time curve (AUC) of ES102 in combination with JS001
Area under the serum concentration time curve (AUC) of ES102 in combination with JS001 will be determined.
Maximum observed serum concentration of ES102 in combination with JS001
Maximum observed serum concentration of ES102 in combination with JS001 will be determined.
Trough observed serum concentration (Ctrough) of ES102 in combination with JS001
Trough observed serum concentration (Ctrough) of ES102 in combination with JS001 will be determined.
Time to Cmax (Tmax) of ES102 in combination with JS001
Time to Cmax (Tmax) of ES102 in combination with JS001 will be determined.
Immunogenicity of ES102 in combination with JS001
Frequency of anti-drug antibodies (ADA) against ES102 in combination with JS001 will be determined.
Anti-tumor activity of ES102 in combination with JS001
Tumor response will be determined by the revised Response Evaluation Criteria in Solid Tumors version 1.1 (RECISTv1.1).
Full Information
NCT ID
NCT04991506
First Posted
July 19, 2021
Last Updated
April 18, 2023
Sponsor
Elpiscience Biopharma, Ltd.
Collaborators
Shanghai Junshi Bioscience Co., Ltd.
1. Study Identification
Unique Protocol Identification Number
NCT04991506
Brief Title
A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors
Official Title
An Open-label, Multicenter, Dose-escalation and Cohort Expansion Phase 1 Clinical Study of ES102 in Combination With JS001 in Patients With Advanced Solid Tumors
Study Type
Interventional
2. Study Status
Record Verification Date
April 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 15, 2021 (Actual)
Primary Completion Date
May 31, 2024 (Anticipated)
Study Completion Date
June 30, 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Elpiscience Biopharma, Ltd.
Collaborators
Shanghai Junshi Bioscience Co., Ltd.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
The purpose of this study is to evaluate the safety, tolerance, Dose-Limiting Toxicity (DLT), Maximum tolerated dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of ES102 (OX40 agonist) in combination with JS001 (anti-PD-1 checkpoint inhibitor) in patients with advanced solid tumors.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Solid Tumor, Neoplasms, Malignant Tumor
Keywords
ES102, JS001, OX40, PD-1, Solid Tumors, Phase 1, INBRX-106
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
82 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Part 1 ES102 Escalation in combination with JS001
Arm Type
Experimental
Arm Description
ES102 will be escalated, in combination with JS001, in patients with advanced solid tumors.
Arm Title
Part 2 ES102 Expansion in combination with JS001
Arm Type
Experimental
Arm Description
Subjects will be treated with ES102 at the RP2D in combination with JS001.
Intervention Type
Drug
Intervention Name(s)
ES102
Intervention Description
The active ingredient of ES102 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4)
Intervention Type
Drug
Intervention Name(s)
JS001
Other Intervention Name(s)
Toripalimab
Intervention Description
JS001 is administered via intravenous injection once every 21 days, every 21 days as a treatment cycle.
Primary Outcome Measure Information:
Title
MTD
Description
Maximum Tolerated Dose (MTD) of ES102 in combination with JS001
Time Frame
2-4 years
Title
Frequency and severity of adverse events of ES102 in combination with JS001
Description
The safety profile of ES102 in combination with JS001 will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.
Time Frame
2-4 years
Title
RP2D
Description
Recommended Phase 2 Dose (RP2D) of ES102 in combination with JS001
Time Frame
2-4 years
Secondary Outcome Measure Information:
Title
Area under the serum concentration time curve (AUC) of ES102 in combination with JS001
Description
Area under the serum concentration time curve (AUC) of ES102 in combination with JS001 will be determined.
Time Frame
2-4 years
Title
Maximum observed serum concentration of ES102 in combination with JS001
Description
Maximum observed serum concentration of ES102 in combination with JS001 will be determined.
Time Frame
2-4 years
Title
Trough observed serum concentration (Ctrough) of ES102 in combination with JS001
Description
Trough observed serum concentration (Ctrough) of ES102 in combination with JS001 will be determined.
Time Frame
2-4 years
Title
Time to Cmax (Tmax) of ES102 in combination with JS001
Description
Time to Cmax (Tmax) of ES102 in combination with JS001 will be determined.
Time Frame
2-4 years
Title
Immunogenicity of ES102 in combination with JS001
Description
Frequency of anti-drug antibodies (ADA) against ES102 in combination with JS001 will be determined.
Time Frame
2-4 years
Title
Anti-tumor activity of ES102 in combination with JS001
Description
Tumor response will be determined by the revised Response Evaluation Criteria in Solid Tumors version 1.1 (RECISTv1.1).
Time Frame
2-4 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
1.Males or females aged ≥18 years.
2.Ability to understand and the willingness to sign a written informed consent form.
3.Subjects with pathological or cytological diagnosed advanced solid tumor, whose disease has progressed despite standard therapies, or for whom no further standard therapy exists, or who is unsuitable for available standard therapies and at least has progressed after receiving first line therapy.
4.PD-L1 by IHC: Parts 1 and Part 2 D2-D3: IHC result mandatory but any score allowed. Part 2 D1: Tumor Proportion Score (TPS) ≥ 1%.
5.At least one measurable lesion is required (RECIST v1.1)
6.Adequate hematologic, coagulation, hepatic and renal function as defined per protocol.
7.Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1.
8.Estimated life expectancy, in the judgment of the investigator, of at least 12 weeks.
9.Male and female subjects of childbearing potential and their spouses must be willing to use feasible contraceptive methods considered effective by the investigator, from the time of signing informed consent and for the duration of study participation through 3 months, following the last dose of study drug. Postmenopausal women are considered to have no fertility potential only if menostasis lasts for at least 12 months.
Exclusion Criteria:
1.Prior exposure to OX40 agonists.
2.Receipt of any anticancer investigational product or any approved anticancer drug(s) or biological product(s) within 4 weeks prior to the first dose of study drug with certain exceptions.
3.Receipt of non-CNS adjuvant radiation therapy within 1 week prior to the first dose, receipt of radiation therapy within 2 weeks or with radiation pneumonia, have not recovered from radiation-related toxicity or still require hormonal treatment for radiation-related toxicity.
4.Known allergies to CHO-produced antibodies, which in the opinion of the Investigator suggests an increased potential for an adverse hypersensitivity to ES102.
5.Subjects with allergic reactions to the active ingredients of JS001 or any of the excipients.
6.Treatment with systemic immunosuppressive medications within 4 weeks prior to the first dose of study drug. Certain exceptions as defined in protocol apply.
7.Receipt of live viral vaccine treatment within 4 weeks prior to the first dose of the study drug.
8.Prior organ allograft transplantations or allogeneic peripheral blood stem cell (PBSC) or bone marrow (BM) transplantation.
9.Subjects with primary or metastatic brain or meningeal tumors.
10.Grade ≥ 3 immune-related adverse events (irAEs) or irAE that lead to discontinuation of prior immunotherapy. Some exceptions as defined per protocol apply.
11.Subject has not recovered from all AEs of previous anticancer therapies to baseline or ≤ Grade 1 per CTCAE v5.0 before the first dose of study drug. Certain exceptions as defined in protocol apply.
12.Hematologic malignancies.
13.Receipt of treatment with G-CSF, GM-CSF, Thrombopoietic drugs or EPO within 14 days prior to the first dose of the study drug.
14.Patients with other malignancies within 2 years before screening shall be excluded in Part B. Some exceptions as defined per protocol apply.
15.Active autoimmune disease or documented history of autoimmune disease that required systemic steroids or other immunosuppressive medications. Certain exceptions as defined in protocol apply.
16.Active interstitial lung disease (ILD) or pneumonitis or a history of ILD or pneumonitis requiring treatment with steroids or other immunosuppressive medications.
17.Clinically significant cardiac condition, including myocardial infarction, uncontrolled angina, cerebrovascular accident, or other acute uncontrolled heart disease < 6 months; left ventricular ejection fraction (LVEF) < 50%; New York Heart Association (NYHA) Class III or IV congestive heart failure; or uncontrolled hypertension.
18.History of pulmonary embolism within 12 weeks prior to the first dose of study drug administration.
19.Major surgery within 4 weeks prior to enrollment on this trial.
20.History of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection for Part 1. Exceptions as defined in protocol for Part 2 will apply.
21.Receiving the systemic anti-infectious drug treatments within 4 weeks prior to the first dose of study drug.
22.Pregnant or nursing females.
23.Any known, documented, or suspected history of substance abuse that would preclude subject from participation, certain exceptions as defined in protocol apply.
24.The subject is inappropriate to participate in this study for other reasons in the judgment of the Investigator.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ning Chen
Phone
86 15021415086
Email
clinical-operation@elpiscience.com
Facility Information:
Facility Name
Jilin Cancer Hospital
City
Changchun
State/Province
Jilin
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ning Zhang
Phone
86 0431-80596067
Email
JPCHIRB@163.com
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors
We'll reach out to this number within 24 hrs